The International Association for the Study of Lung Cancer held the 2019 World Conference on Lung Cancer on September 7 to 10 in Barcelona, Spain. This annual conference is the world’s largest international gathering in the field of lung cancer and thoracic oncology.
In this podcast, Dr. Vamsidhar Velcheti discusses an early phase I study on a new drug, AMG 510, that was presented at the conference. This drug is a type of targeted therapy, which means it targets specific genes, proteins, or the tissue environment that contributes to cancer growth.
-
What is the KRAS G12C genetic mutation, and why is it important? [2:18]
-
What was the goal of this study and what did it find? [3:17]
-
What will happen next as researchers continue to study this drug? [5:12]
Dr. Velcheti is Associate Professor and Director of Thoracic Medical Oncology at NYU Langone’s Perlmutter Cancer Center. He is a member of the Cancer.Net Editorial Board and is also the recipient of a 2012 Young Investigator Award and a 2015 Career Development Award from Conquer Cancer, the ASCO Foundation. Dr. Velcheti has no relationships to disclose related to this drug.
Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts on Apple Podcasts or Google Play. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.